Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

146 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Irinotecan plus carboplatin for patients with carcinoma of unknown primary site.
Yonemori K, Ando M, Yunokawa M, Hirata T, Kouno T, Shimizu C, Tamura K, Katsumata N, Hirakawa A, Matsumoto K, Yamanaka Y, Arioka H, Fujiwara Y. Yonemori K, et al. Among authors: yunokawa m. Br J Cancer. 2009 Jan 13;100(1):50-5. doi: 10.1038/sj.bjc.6604829. Epub 2008 Dec 16. Br J Cancer. 2009. PMID: 19088717 Free PMC article. Clinical Trial.
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with endometrial cancer.
Koppikar S, Oaknin A, Babu KG, Lorusso D, Gupta S, Wu LY, Rajabto W, Harano K, Hong SH, Malik RA, Strebel H, Aggarwal IM, Lai CH, Dejthevaporn T, Tangjitgamol S, Cheng WF, Chay WY, Benavides D, Hashim NM, Moon YW, Yunokawa M, Anggraeni TD, Wei W, Curigliano G, Maheshwari A, Mahantshetty U, Sheshadri S, Peters S, Yoshino T, Pentheroudakis G. Koppikar S, et al. Among authors: yunokawa m. ESMO Open. 2023 Feb;8(1):100774. doi: 10.1016/j.esmoop.2022.100774. Epub 2023 Jan 23. ESMO Open. 2023. PMID: 36696825 Free PMC article.
Development and verification of a prediction model using serum tumor markers to predict the response to chemotherapy of patients with metastatic or recurrent breast cancer.
Yonemori K, Katsumata N, Noda A, Uno H, Yunokawa M, Nakano E, Kouno T, Shimizu C, Ando M, Tamura K, Takeuchi M, Fujiwara Y. Yonemori K, et al. Among authors: yunokawa m. J Cancer Res Clin Oncol. 2008 Nov;134(11):1199-206. doi: 10.1007/s00432-008-0401-7. Epub 2008 Jun 5. J Cancer Res Clin Oncol. 2008. PMID: 18528707 Clinical Trial.
The incidence and management of metachronous testicular germ cell tumors in patients with extragonadal germ cell tumors.
Hashimoto K, Fujimoto H, Kouno T, Koseki M, Yonemori K, Hirata T, Yunokawa M, Shimizu C, Katsumata N, Tamura K, Ando M, Takeuchi M, Nakanishi H, Komiyama M, Nakagawa T, Fujiwara Y. Hashimoto K, et al. Among authors: yunokawa m. Urol Oncol. 2012 May-Jun;30(3):319-24. doi: 10.1016/j.urolonc.2010.02.008. Epub 2010 May 14. Urol Oncol. 2012. PMID: 20471872
The notorious "drug lag" for oncology drugs in Japan.
Yonemori K, Hirakawa A, Ando M, Hirata T, Yunokawa M, Shimizu C, Katsumata N, Tamura K, Fujiwara Y. Yonemori K, et al. Among authors: yunokawa m. Invest New Drugs. 2011 Aug;29(4):706-12. doi: 10.1007/s10637-011-9638-0. Epub 2011 Feb 1. Invest New Drugs. 2011. PMID: 21286780
Phase I and pharmacokinetic study of nab-paclitaxel, nanoparticle albumin-bound paclitaxel, administered weekly to Japanese patients with solid tumors and metastatic breast cancer.
Ando M, Yonemori K, Katsumata N, Shimizu C, Hirata T, Yamamoto H, Hashimoto K, Yunokawa M, Tamura K, Fujiwara Y. Ando M, et al. Among authors: yunokawa m. Cancer Chemother Pharmacol. 2012 Feb;69(2):457-65. doi: 10.1007/s00280-011-1726-5. Epub 2011 Aug 19. Cancer Chemother Pharmacol. 2012. PMID: 21853310 Clinical Trial.
146 results